Effect of Zinc on Hyperbilirubinemia of Newborns, a Randomized Double Blinded Clinical Trial

• Published in: Current health sciences journal Vol. 46; no. 3; pp. 250 - 254
• Main Authors: Khoshnevisasl, Parisa, Sadeghzadeh, Mansour, Kamali, Koorosh, Moeinian, Maysam
• Format: Journal Article
• Language: English
• Published: Medical University Publishing House Craiova 01.07.2020
• Subjects: Original Paper
• ISSN: 2067-0656; 2069-4032
• DOI: 10.12865/CHSJ.46.03.06

BACKGROUNDJaundice is one of the most common causes of hospitalization in newborn infants. Zinc may have a possible role as a cofactor of enzymes in the metabolism of bilirubin and can prevent red blood cell destruction as an antioxidant agent. The present study aims to investigate the effect of zinc in the treatment of neonatal hyperbilirubinemia. Material&Methods: In this double-blind, randomized clinical trial, 112 healthy newborns with idiopathic neonatal hyperbilirubinemia were divided into two groups receiving zinc and placebo. The case and control group received 10mg of zinc and placebo daily. The total bilirubin levels in the second, third, fourth and fifth day and duration of hospitalization and phototherapy were compared. RESULTSThe mean total bilirubin value in the second to fifth days in the zinc group were 11.95±2.35, 9.49±1.79, 8.54±1.63 and 8.64±0.96 respectively, and in the placebo group were 12.95±2.73, 9.88±2.35, 9.5±2.9 and 10.16±0.86 respectively and there was no significant difference between two groups. The duration of phototherapy and hospitalization in the zinc and placebo groups did not show any significant difference. CONCLUSIONWe did not find a significant reduction in serum bilirubin levels nor the duration of hospitalization in neonates receiving zinc sulfate compared to control group.